Drug Profile
Glibenclamide - AMMTeK
Alternative Names: AMGLIDIA; AmglidiaLatest Information Update: 25 Feb 2022
Price :
$50
*
At a glance
- Originator AMMTeK
- Developer AMMTeK; Assistance Publique Hopitaux de Paris
- Class Antihyperglycaemics; Benzamides; Small molecules; Sulfonylureas; Vascular disorder therapies
- Mechanism of Action KATP channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 25 Feb 2022 Launched for Type 2 diabetes mellitus (In adolescents, In children, In infants, In neonates) in France (PO) prior to February 2022
- 25 Feb 2022 Registered for Type 2 diabetes mellitus (In adolescents, In children, In infants, In neonates) in France (PO) prior to February 2022
- 01 Jul 2019 Chemical structure information added